Ascendis Pharma A/s Stock News

Equities analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($2.65) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($2.16) and the lowest is ($3.05). Ascendis Pharma A/S posted earnings of ($3.15) per share in the []

Ascendis Pharma A/S (NASDAQ:ASND) concluded the trading at $135.61 on Friday, December 03 with a fall of -7.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $145.89 and 5Y monthly beta was reading 0.79 with its price kept floating in the Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks Read More »

Ascendis Pharma A/S (NASDAQ:ASND) and Sol-Gel Technologies (NASDAQ:SLGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares Ascendis Pharma A/S and Sol-Gel Technologies net margins, return on equity [] The post Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL) appeared first on ETF Daily News .

HOUSTON and SINGAPORE , Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors. "I am delighted to welcome Jan to Hummingbird''s Board of Directors as our Chairman. His extensive experience leading and scaling businesses spanning from drug discovery to commercial stage companies is invaluable to Hummingbird Bioscience, as we chart our next stage of growth and pursue our mission of bringing precision medicines to patients," said Piers Ingram , CEO and co-founder of Hummingbird Bioscience. Mr. Mikkelsen currently serves as President, CEO and Board member of Ascendis Pharma, a pharmaceutical company he founded in 2007. He was previously President and CEO of LifeCycle Pharma, President of the Pharmaceutical Division of Maxygen, Inc., as well as co-founder of ProFound Pharma where he also served as co-CEO.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average recommendation of Buy from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among []

Infill and extension drilling intended to upgrade, expand and improve grade of the existing resource Infill and extension drilling intended to upgrade, expand and improve grade of the existing resourc

Senior mining finance & M&A professional to augment growth opportunities Senior mining finance & M&A professional to augment growth opportunities

Cantor Fitzgerald reaffirmed their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Thursday morning, Zacks.com reports. ASND has been the subject of a number of other research reports. Credit Suisse Group cut their target price on shares of Ascendis Pharma A/S from $185.00 to $179.00 and set an []

Ascendis Pharma A/S (NASDAQ:ASND)s stock had its overweight rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday, Zacks.com reports. ASND has been the topic of several other research reports. Bank of America downgraded Ascendis Pharma A/S from a buy rating to a neutral rating and raised their price []

Ascendis Pharma A/S (NASDAQ: ASND ) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP). Hypoparathyroidism is a condition in which the body produces abnormally low levels of PTH, the key to regulating and maintaining a balance of two calcium and phosphorus. TransCon PTH is an investigational once-daily Full story available on Benzinga.com

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by SVB Leerink from $182.00 to $190.00 in a research note released on Monday morning, Analyst Price Targets reports. The brokerage currently has an outperform rating on the biotechnology companys stock. ASND has been the subject of several other research reports. JPMorgan Chase & Co. increased []

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.

58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.

Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will post earnings of ($2.78) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($1.93) and the lowest is ($3.71). Ascendis Pharma A/S reported earnings of ($3.15) per share during the same []

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Confe